Biological and pharmaceutical systems operate under extreme safety, regulatory, and precision constraints — involving complex multi-stage processes from genomic analysis to biologics manufacturing, from sterile processing to cold-chain distribution. Yet today, bio-pharmaceutical governance is nondeterministic, fragmented, and disconnected from the physical substrates that determine product safety, sterility assurance, and contamination response. Existing systems — GMP protocols, GLP frameworks, FDA/EMA guidelines, and batch management platforms — operate in silos, lack cross-vertical awareness, and provide no replay-identical audit capability. I introduce Lume-LifeBio, to my knowledge, the first deterministic governance substrate for biological, pharmaceutical, and biomanufacturing systems. Built on the Lume-V governance layer and the Lume-Ops universal operational substrate, Lume-LifeBio integrates genomic pipeline governance, bioprocessing and bioreactor control, sterile manufacturing safety, cold-chain integrity for biologics, cleanroom environmental control, and recall propagation into a single replay-identical state machine. It enforces biological invariants, bioprocess envelopes, deterministic multi-agent arbitration, override logic with deterministic rollback, and certificate-based auditability across the full biomanufacturing pipeline — from genomic input to bioprocessing to manufacturing to cold-chain to clinical delivery.
Ronald Jason Andrews (Thu,) studied this question.